News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Lock Kenneth A.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/08/2023 |
4
| Lock Kenneth A. (Chief Commercial Officer) has filed a Form 4 on Arcutis Biotherapeutics, Inc.|
Txns:
| Sold 831 shares
@ $15.2636, valued at
$12.7k
|
|
| 03/06/2023 |
4
| Lock Kenneth A. (Chief Commercial Officer) has filed a Form 4 on Arcutis Biotherapeutics, Inc.|
Txns:
| Granted 21,000 shares
@ $0
Granted 55,800 options to buy
@ $15.82, valued at
$882.8k
|
|
| 03/02/2023 |
4
| Lock Kenneth A. (Chief Commercial Officer) has filed a Form 4 on Arcutis Biotherapeutics, Inc.|
Txns:
| Sold 936 shares
@ $16.1663, valued at
$15.1k
Sold 1,414 shares
@ $15.8182, valued at
$22.4k
Sold 18 shares
@ $16.52, valued at
$297.4 |
|
| 03/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/16/2021 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 10/27/2020 |
4
| Lock Kenneth A. (Chief Commercial Officer) has filed a Form 4 on Arcutis Biotherapeutics, Inc.|
Txns:
| Exercised 2,668 options to buy
@ $6.52, valued at
$17.4k
|
|
| 10/23/2020 |
4
| Lock Kenneth A. (Chief Commercial Officer) has filed a Form 4 on Arcutis Biotherapeutics, Inc.|
Txns:
| Exercised 2,695 options to buy
@ $6.52, valued at
$17.6k
|
|
| 10/16/2020 |
4
| Lock Kenneth A. (Chief Commercial Officer) has filed a Form 4 on Arcutis Biotherapeutics, Inc.|
Txns:
| Exercised 7,500 options to buy
@ $6.52, valued at
$48.9k
|
|
| 03/03/2020 |
4
| Lock Kenneth A. (Chief Commercial Officer) has filed a Form 4 on Arcutis Biotherapeutics, Inc.|
Txns:
| Granted 9,000 shares
@ $0
Granted 27,000 options to buy
@ $27.61, valued at
$745.5k
|
|
| 01/30/2020 |
3
| Lock Kenneth A. (Chief Commercial Officer) has filed a Form 3 on Arcutis Biotherapeutics, Inc. |
|
|